The neuroprotective effect of liraglutide is mediated by glucagon-like peptide 1 receptor-mediated activation of cAMP/PKA/CREB pathway

Cellular Physiology and Biochemistry

Volumn 36, Issue 6, 2015, Pages 2366-2378

  Bao, Yi ^a   Jiang, Lei ^a   Chen, Haiyan ^a   Zou, Junjie ^a   Liu, Zhimin ^a   Shi, Yongquan ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

AGEs; Astrocytes; cAMP; GLP 1; Liraglutide

Indexed keywords

9 (TETRAHYDRO 2 FURYL)ADENINE; ADVANCED GLYCATION END PRODUCT; CASPASE 3; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE; NEUROPROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; AUTACOID; CYTOKINE; GLUCAGON RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; COLORIMETRY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; MTT ASSAY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; METABOLISM; SECRETION (PROCESS); SIGNAL TRANSDUCTION; WISTAR RAT;

RATTUS;

ANIMALS; ASTROCYTES; CELL DEATH; CELL PROLIFERATION; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYTOKINES; GLYCOSYLATION END PRODUCTS, ADVANCED; INFLAMMATION MEDIATORS; LIRAGLUTIDE; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION;

EID: 84939622336     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430199     Document Type: Article

References (50)

1. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM: Diabetes mellitus and the risk of dementia: The rotterdam study. Neurology 1999;53:1937-1942.
2. Butterfield DA, Di Domenico F, Barone E: Elevated risk of type 2 diabetes for development of alzheimer disease: A key role for oxidative stress in brain. Biochim Biophys Acta 2014;1842:1693-1706.
3. De Felice FG, Ferreira ST: Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to alzheimer disease. Diabetes 2014;63:2262-2272.
4. Singh VP, Bali A, Singh N, Jaggi AS: Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 2014;18:1-14.
5. Choei H, Sasaki N, Takeuchi M, Yoshida T, Ukai W, Yamagishi S, Kikuchi S, Saito T: Glyceraldehyde-derived advanced glycation end products in alzheimer's disease. Acta Neuropathol 2004;108:189-193.
6. Takeda A, Yasuda T, Miyata T, Goto Y, Wakai M, Watanabe M, Yasuda Y, Horie K, Inagaki T, Doyu M, Maeda K, Sobue G: Advanced glycation end products co-localized with astrocytes and microglial cells in alzheimer's disease brain. Acta Neuropathol 1998;95:555-558.
7. Takeuchi M, Yamagishi S: Possible involvement of advanced glycation end-products (ages) in the pathogenesis of alzheimer's disease. Curr Pharm Des 2008;14:973-978.
8. Li J, Liu D, Sun L, Lu Y, Zhang Z: Advanced glycation end products and neurodegenerative diseases: Mechanisms and perspective. J Neurol Sci 2012;317:1-5.
9. Drucker DJ: Glucagon-like peptides. Diabetes 1998;47:159-169.
10. Rondas D, D'Hertog W, Overbergh L, Mathieu C: Glucagon-like peptide-1: Modulator of beta-cell dysfunction and death. Diabetes Obes Metab 2013;15:185-192.
11. Lonze BE, Ginty DD: Function and regulation of creb family transcription factors in the nervous system. Neuron 2002;35:605-623.
12. Yu Z, Jin T: New insights into the role of camp in the production and function of the incretin hormone glucagon-like peptide-1 (glp-1). Cell Signal 2010;22:1-8.
13. Eckerle Mize DL, Salehi M: The place of glp-1-based therapy in diabetes management: Differences between dpp-4 inhibitors and glp-1 receptor agonists. Curr Diab Rep 2013;13:307-318.
14. Duarte AI, Candeias E, Correia SC, Santos RX, Carvalho C, Cardoso S, Placido A, Santos MS, Oliveira CR, Moreira PI: Crosstalk between diabetes and brain: Glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. Biochim Biophys Acta 2013;1832:527-541.
15. Hunter K, Holscher C: Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 2012;13:33.
16. McClean PL, Holscher C: Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged app/ps1 mice, a model of alzheimer's disease. Neuropharmacology 2014;76:57-67.
17. Parthsarathy V, Holscher C: The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. Eur J Pharmacol 2013;700:42-50.
18. Avila-Munoz E, Arias C: When astrocytes become harmful: Functional and inflammatory responses that contribute to alzheimer's disease. Ageing Res Rev 2014;18C:29-40.
19. Jiang JM, Wang Z, Li DD: Effects of ages on oxidation stress and antioxidation abilities in cultured astrocytes. Biomed Environ Sci 2004;17:79-86.
20. Wang Z, Li DD, Liang YY, Wang DS, Cai NS: Activation of astrocytes by advanced glycation end products: Cytokines induction and nitric oxide release. Acta Pharmacol Sin 2002;23:974-980.
21. Li XH, Lv BL, Xie JZ, Liu J, Zhou XW, Wang JZ: Ages induce alzheimer-like tau pathology and memory deficit via rage-mediated gsk-3 activation. Neurobiol Aging 2012;33:1400-1410.
22. Makita Z, Vlassara H, Cerami A, Bucala R: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992;267:5133-5138.
23. Caruso C, Durand D, Schioth HB, Rey R, Seilicovich A, Lasaga M: Activation of melanocortin 4 receptors reduces the inflammatory response and prevents apoptosis induced by lipopolysaccharide and interferongamma in astrocytes. Endocrinology 2007;148:4918-4926.
24. McCarthy KD, de Vellis J: Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 1980;85:890-902.
25. Liu D, Jiang H, Grange RW: Genistein activates the 3',5'-cyclic adenosine monophosphate signaling pathway in vascular endothelial cells and protects endothelial barrier function. Endocrinology 2005;146:1312-1320.
26. Liu D, Zhen W, Yang Z, Carter JD, Si H, Reynolds KA: Genistein acutely stimulates insulin secretion in pancreatic beta-cells through a camp-dependent protein kinase pathway. Diabetes 2006;55:1043-1050.
27. Gengler S, McClean PL, McCurtin R, Gault VA, Holscher C: Val(8)glp-1 rescues synaptic plasticity and reduces dense core plaques in app/ps1 mice. Neurobiol Aging 2012;33:265-276.
28. Gault VA, Flatt PR, O'Harte FP: Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun 2003;308:207-213.
29. Perry TA, Greig NH: A new alzheimer's disease interventive strategy: Glp-1. Curr Drug Targets 2004;5:565-571.
30. Sarkar S, Fekete C, Legradi G, Lechan RM: Glucagon like peptide-1 (7-36) amide (glp-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res 2003;985:163-168.
31. Cho YM, Fujita Y, Kieffer TJ: Glucagon-like peptide-1: Glucose homeostasis and beyond. Annu Rev Physiol 2014;76:535-559.
32. Xu WW, Guan MP, Zheng ZJ, Gao F, Zeng YM, Qin Y, Xue YM: Exendin-4 alleviates high glucose-induced rat mesangial cell dysfunction through the ampk pathway. Cell Physiol Biochem 2014;33:423-432.
33. Holscher C: Central effects of glp-1: New opportunities for treatments of neurodegenerative diseases. J Endocrinol 2014;221:T31-41.
34. McClean PL, Parthsarathy V, Faivre E, Holscher C: The diabetes drug liraglutide prevents degenerative processes in a mouse model of alzheimer's disease. J Neurosci 2011;31:6587-6594.
35. Barnham KJ, Masters CL, Bush AI: Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004;3:205-214.
36. Fischer R, Maier O: Interrelation of oxidative stress and inflammation in neurodegenerative disease: Role of tnf. Oxid Med Cell Longev 2015;2015:610813.
37. Hsieh HL, Yang CM: Role of redox signaling in neuroinflammation and neurodegenerative diseases. Biomed Res Int 2013;2013:484613.
38. Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, Greig NH: Evidence of glp-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007;203:293-301.
39. Li Y, Tweedie D, Mattson MP, Holloway HW, Greig NH: Enhancing the glp-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J Neurochem 2010;113:1621-1631.
40. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH: Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002;302:881-888.
41. Cole GM, Morihara T, Lim GP, Yang F, Begum A, Frautschy SA: Nsaid and antioxidant prevention of alzheimer's disease: Lessons from in vitro and animal models. Ann N Y Acad Sci 2004;1035:68-84.
42. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT: Inflammation and alzheimer's disease. Arch Pharm Res 2010;33:1539-1556.
43. Ayasolla K, Khan M, Singh AK, Singh I: Inflammatory mediator and beta-amyloid (25-35)-induced ceramide generation and inos expression are inhibited by vitamin e. Free Radic Biol Med 2004;37:325-338.
44. Luheshi NM, Kovacs KJ, Lopez-Castejon G, Brough D, Denes A: Interleukin-1alpha expression precedes il-1beta after ischemic brain injury and is localised to areas of focal neuronal loss and penumbral tissues. J Neuroinflammation 2011;8:186.
45. Matousek SB, Ghosh S, Shaftel SS, Kyrkanides S, Olschowka JA, O'Banion MK: Chronic il-1beta-mediated neuroinflammation mitigates amyloid pathology in a mouse model of alzheimer's disease without inducing overt neurodegeneration. J Neuroimmune Pharmacol 2012;7:156-164.
46. Iwai T, Ito S, Tanimitsu K, Udagawa S, Oka J: Glucagon-like peptide-1 inhibits lps-induced il-1beta production in cultured rat astrocytes. Neurosci Res 2006;55:352-360.
47. Zhao L, Brinton RD: Suppression of proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha in astrocytes by a v1 vasopressin receptor agonist: A camp response element-binding proteindependent mechanism. J Neurosci 2004;24:2226-2235.
48. Wang L, Liu Y, Yang J, Zhao H, Ke J, Tian Q, Zhang L, Wen J, Wei R, Hong T: Glp-1 analog liraglutide enhances proinsulin processing in pancreatic beta-cells via a pka-dependent pathway. Endocrinology 2014;155:3817-3828.
49. Fujita H, Morii T, Fujishima H, Sato T, Shimizu T, Hosoba M, Tsukiyama K, Narita T, Takahashi T, Drucker DJ, Seino Y, Yamada Y: The protective roles of glp-1r signaling in diabetic nephropathy: Possible mechanism and therapeutic potential. Kidney Int 2014;85:579-589.
50. Li Y, Bader M, Tamargo I, Rubovitch V, Tweedie D, Pick CG, Greig NH: Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. J Neurochem DOI:10.1111/jnc.13169.